Search company, investor...
EmeraMed company logo



Unattributed - III | Alive

Total Raised


Last Raised

$270K | 6 yrs ago

About EmeraMed

EmeraMed, formerly Ermes Medical Company, is a biotechnology firm developing metal chelator and anti oxidant NBMI (Irminix). The Company is working to obtain marketing authorization in the EU and the US for the treatment of mercury toxicity. Phase 1 clinical studies have been performed. Phase 2 is being performed Fall 2015.

Headquarters Location

7/8 Wilton Terrace

Dublin, 2,


(859) 266-9200

Missing: EmeraMed's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: EmeraMed's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing EmeraMed

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

EmeraMed is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

EmeraMed Patents

EmeraMed has filed 1 patent.

The 3 most popular patent topics include:

  • Amyotrophic lateral sclerosis
  • Neurological disorders
  • Rare diseases
patents chart

Application Date

Grant Date


Related Topics




Muscarinic antagonists, Respiratory therapy, Combination drugs, Bronchodilators, Lung disorders


Application Date


Grant Date



Related Topics

Muscarinic antagonists, Respiratory therapy, Combination drugs, Bronchodilators, Lung disorders



Latest EmeraMed News

Rate of arthritis increased with number of dental amalgam filling surfaces

Jun 24, 2021

Disclosures: Kennedy reports he owns real estate in, has stock or stock options in and is a board member of EmeraMed Ltd. David A. Geier and Mark R. Geier, MD, are directors of the nonprofit Institute of Chronic Illness Inc. and CoMeD Inc.; and own shares in EmeraMed Ltd. This research was funded by a grant from the International Academy of Oral Medicine and Toxicology to the Institute of Chronic Illnesses Inc. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact . Back to Healio The rate of reported arthritis increased with the number of dental amalgam filling surfaces found in adults, with the rate peaking at four to seven dental amalgam filling surfaces before decreasing, according to results. David A. Geier and Mark R. Geier, MD, examined patient demographics, oral health examinations and medical condition surveys relating to arthritis diagnosis among 86,305,425 weighted-persons with one or more dental amalgam filling surfaces (exposed group) and 32,201,088 weighted-persons with one or more other dental filling surfaces (unexposed group) in the 2015 to 2016 National Health and Nutritional Examination Survey. Researchers employed survey logistic regression and survey frequency modeling with and without adjustment of covariates. Results showed patients in the exposed group had a 7.68-fold and 4.89-fold increase in the unadjusted and adjusted models, respectively, for the risk of reported arthritis. Researchers found a six-fold significant increase in arthritis in the exposed group compared with the unexposed group, as well as a significant bimodal dose-dependent relationship between dental amalgam filling surfaces and the arthritis rate. Although the rate of reported arthritis increased with increasing dental amalgam filling surfaces, researchers noted a decrease in the rate of reported arthritis in patients with greater than six dental amalgam filling surfaces. The rate of reported arthritis significantly decreased among patients with greater than 13 dental amalgam filling surfaces compared with patients who had four to seven dental amalgam filling surfaces, according to results. Researchers found a significant association between dental amalgam filling surfaces and arthritis risk, as well as a dose-dependent dental amalgam filling surface associated immune-stimulation/immune-suppression with arthritis risk. Researchers estimated an additional $96,835814 are spent on annual medical costs and $184,797,680 are lost in annual wages from reported new onset arthritis associated with dental amalgam filling surfaces. David Kennedy “Because mercury causes a cascade of damage, an incredible amount of harm can result from a minute exposure to mercury. In addition, mercury displaces essential metals like iron inside the mitochondria. Iron then short-circuits energy production into free radical oxidation which leads to fatigue and, eventually, mitochondria death,” David Kennedy, DDS, past president of the International Academy of Oral Medicine and Toxicology, told Healio Orthopedics. “Once mercury is banned, over time, we will have a whole new perspective on the wide-ranging damage minute exposures have caused.” References:

EmeraMed Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

EmeraMed Rank

EmeraMed Frequently Asked Questions (FAQ)

  • Where is EmeraMed's headquarters?

    EmeraMed's headquarters is located at 7/8 Wilton Terrace, Dublin.

  • What is EmeraMed's latest funding round?

    EmeraMed's latest funding round is Unattributed - III.

  • How much did EmeraMed raise?

    EmeraMed raised a total of $5.9M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.